Wolverine Stack Blood Work — Labs to Check Before & After

Research protocols involving growth hormone secretagogues, nootropic peptides, and immune modulators. Commonly referenced as a 'Wolverine Stack' in performance research communities. Require baseline and follow-up laboratory monitoring that most researchers overlook entirely. A pre-cycle panel catches contraindications (elevated liver enzymes, suppressed testosterone, borderline hematocrit) before you inject anything. A post-cycle panel catches suppression, hepatotoxicity, or lipid dysregulation while there's still time to adjust dosing or discontinue safely. Our team has reviewed hundreds of research protocols in this space. The pattern is consistent: researchers who skip blood work are the ones who report adverse events they could have prevented.

What labs should you check before and after running a Wolverine Stack?

Before starting any peptide research protocol involving MK-677, Cerebrolysin, or immune peptides like Thymalin, obtain a baseline panel measuring total and free testosterone, liver enzymes (AST, ALT, GGT), lipid profile (LDL, HDL, triglycerides), fasting glucose and insulin, complete blood count with differential, and thyroid function (TSH, free T3, free T4). Repeat the panel at 4–6 weeks mid-cycle and 4 weeks post-cycle to detect suppression, organ stress, or metabolic disruption before it becomes irreversible.

The mistake most researchers make isn't skipping blood work entirely. It's ordering the wrong markers or testing at the wrong intervals. A CBC without a metabolic panel misses liver enzyme elevation. A post-cycle panel drawn two weeks after the last dose misses delayed suppression that shows up at week six. The rest of this article covers exactly which biomarkers matter for each compound class, when to draw each panel, and what threshold values require protocol adjustment or discontinuation.

Pre-Cycle Baseline: The 12 Markers That Matter

Your baseline panel establishes normal ranges specific to you. Not population averages. Growth hormone secretagogues like MK-677 elevate fasting glucose and insulin within 2–4 weeks. If your baseline fasting glucose is already 105 mg/dL (pre-diabetic threshold: 100–125 mg/dL), adding a ghrelin mimetic that raises glucose another 8–12 mg/dL pushes you into sustained hyperglycemia.

The 12 essential pre-cycle markers:

Hormone Panel

• Total testosterone: establishes baseline before potential suppression from stacked compounds
• Free testosterone: more sensitive to early suppression than total testosterone alone
• Estradiol (sensitive assay): elevated estradiol at baseline suggests aromatisation issues that peptide stacks can compound
• LH and FSH: detects pre-existing hypogonadism that contraindicates further suppressive protocols

Metabolic Panel

• Fasting glucose: MK-677 raises glucose 8–15 mg/dL on average. Baseline >100 mg/dL is a relative contraindication
• Fasting insulin: elevated insulin (>25 μIU/mL) suggests insulin resistance that growth hormone secretagogues worsen
• HbA1c: three-month glucose average. More reliable than single fasting glucose for detecting impaired glucose tolerance

Liver Function

• AST and ALT: baseline >40 U/L suggests pre-existing hepatic stress
• GGT (gamma-glutamyl transferase): more specific for liver damage than AST/ALT alone, which can be elevated from muscle breakdown

Lipid Panel

• LDL cholesterol, HDL cholesterol, triglycerides: certain peptide combinations (especially when stacked with anabolic agents) shift lipid ratios unfavourably

Blood Health

• Complete blood count with differential: establishes baseline hematocrit (peptides affecting erythropoiesis can raise hematocrit to dangerous levels >54%), white blood cell count, and platelet function

We've found that researchers who order a 'basic metabolic panel' from a standard lab often miss GGT, free testosterone, and fasting insulin. The three markers most likely to reveal contraindications specific to peptide protocols.

Mid-Cycle Monitoring: The 4–6 Week Window

The second panel timing is critical. Draw too early (week 2) and you miss compound-specific effects that take 3–4 weeks to manifest. Draw too late (week 10+) and you've spent months under metabolic stress you could have mitigated at week 5.

Mid-cycle labs (drawn at 4–6 weeks into the protocol) must retest:

Glucose metabolism markers. MK-677's glucose elevation peaks at week 4–6 before partial adaptation occurs. If fasting glucose rises >15 mg/dL from baseline or crosses 126 mg/dL (diabetic threshold), dose reduction or discontinuation is indicated. Fasting insulin >30 μIU/mL mid-cycle suggests insulin resistance is worsening, not stabilising.

Liver enzymes. AST/ALT elevations from peptide protocols are uncommon but dose-dependent. Any elevation >2× upper limit of normal (ULN) requires immediate protocol review. GGT elevation specifically suggests hepatobiliary stress rather than muscle-derived enzyme release.

Testosterone and estradiol. Some peptide combinations (particularly when stacked with SARMs or prohormones, which are outside the scope of pure peptide research but common in practice) suppress the hypothalamic-pituitary-gonadal axis. Total testosterone dropping >20% from baseline or free testosterone <50 pg/mL mid-cycle indicates suppression is occurring.

Hematocrit. Compounds affecting erythropoiesis (indirectly through IGF-1 elevation) can raise hematocrit. Levels >52% increase thrombotic risk and warrant hydration optimisation or phlebotomy.

Researchers using Dihexa or other nootropic peptides sometimes skip mid-cycle labs because cognitive compounds 'don't affect hormones'. But stacked protocols create synergistic metabolic effects that single-agent models don't predict.

Post-Cycle Recovery: The 4-Week Retest

Post-cycle labs drawn immediately after the last injection miss delayed suppression and recovery kinetics. The physiologically relevant window is 4 weeks after the final dose. Long enough for acute compound effects to clear but early enough to detect whether natural hormone production has resumed.

The post-cycle panel must retest all baseline markers with particular focus on:

Testosterone recovery. Total and free testosterone should return to within 10–15% of baseline by week 4 post-cycle. Persistent suppression (total testosterone <300 ng/dL or free testosterone <50 pg/mL) may require medical intervention.

Liver enzyme normalisation. AST, ALT, and GGT should return to baseline or below within 4–6 weeks. Persistent elevation suggests either ongoing hepatotoxicity or unrelated liver pathology that the peptide protocol unmasked.

Lipid recovery. HDL typically recovers faster than LDL. A post-cycle lipid panel showing worsening LDL/HDL ratio compared to mid-cycle suggests the protocol caused lasting metabolic disruption.

Glucose and insulin normalisation. Fasting glucose should return to baseline within 2–3 weeks after stopping MK-677. Persistent elevation (fasting glucose >100 mg/dL post-cycle when baseline was <95 mg/dL) suggests the protocol induced insulin resistance that didn't fully reverse.

Our experience guiding researchers through these protocols shows that skipping the 4-week post-cycle panel is the single most common mistake. They assume 'feeling fine' means full recovery, when hormone panels often show lingering suppression that subjective assessment misses entirely.

Wolverine Stack Blood Work Labs Check Before After: Peptide-Specific Considerations

What If: Wolverine Stack Blood Work Scenarios

What If My Mid-Cycle Glucose Is 15 mg/dL Higher Than Baseline?

Reduce your growth hormone secretagogue dose by 30–50% immediately and retest fasting glucose in two weeks. If glucose remains >15 mg/dL above baseline or crosses 126 mg/dL (diabetic threshold), discontinue the GH secretagogue component entirely. Elevated glucose from MK-677 or similar compounds results from increased hepatic glucose output and reduced insulin sensitivity. Continuing the protocol at the same dose compounds insulin resistance that may not fully reverse post-cycle.

What If My Testosterone Drops 25% Mid-Cycle on a 'Non-Suppressive' Peptide Stack?

First, verify the result. Draw a second testosterone panel (ideally early morning, fasted) to rule out diurnal variation or lab error. If confirmed, this suggests either (1) one of the stacked compounds is indirectly suppressive via prolactin elevation or estradiol conversion, or (2) the stack includes a research compound marketed as a peptide but functioning as a SARM or prohormone. Check prolactin and estradiol on the retest. Prolactin >20 ng/mL or estradiol >50 pg/mL in men indicates the mechanism. Address with dose reduction or an aromatase inhibitor if estradiol-driven.

What If My Liver Enzymes Are Elevated Post-Cycle but Were Normal Mid-Cycle?

This is uncommon but not impossible. Delayed hepatotoxicity can occur if the protocol included lipophilic compounds that accumulate in hepatic tissue. Retest liver enzymes (AST, ALT, GGT) plus bilirubin and alkaline phosphatase in two weeks. If enzymes continue rising or exceed 3× upper limit of normal, obtain abdominal ultrasound to rule out structural liver pathology. Avoid alcohol, acetaminophen, and other hepatotoxic substances during recovery. Persistent elevation beyond 8 weeks post-cycle warrants hepatology referral.

The Unflinching Truth About Peptide Stack Monitoring

Here's the honest answer: most researchers running 'Wolverine Stacks' or similar multi-peptide protocols never draw a single lab panel. The marketing around peptides emphasises 'research purposes only' disclaimers while simultaneously promoting stacks designed for performance outcomes. Creating a grey zone where users treat these compounds like supplements rather than research chemicals with real metabolic effects. We've reviewed blood work from hundreds of researchers in this space. The consistent finding: glucose dysregulation, transient testosterone suppression, and lipid shifts occur far more frequently than the anecdotal reports suggest. The absence of reported side effects isn't evidence of safety. It's evidence that most users aren't monitoring.

The bottom line: if you're not willing to spend $200–300 on three lab panels (pre, mid, post), you're not in a position to run a research protocol safely. Blood work isn't optional monitoring for 'advanced users'. It's the baseline standard that separates informed research from reckless self-experimentation. Every compound in a typical Wolverine Stack. MK-677, Cerebrolysin, Thymalin, metabolic peptides like Tesofensine. Has documented metabolic effects that require laboratory confirmation, not subjective self-assessment.

Our team's perspective after years in this field: the researchers who experience the fewest adverse events are the ones who treat peptide protocols with the same monitoring rigour as pharmaceutical trials. That means pre-cycle contraindication screening, mid-cycle dose adjustment based on biomarkers, and post-cycle confirmation of full recovery. It's not glamorous. It doesn't fit the narrative of 'biohacking' sold on forums. But it's the difference between a controlled research outcome and an uncontrolled metabolic experiment.

Wolverine stack blood work labs check before after. Those seven words represent the gap between informed peptide research and hope-based dosing. If the protocol matters enough to invest in high-purity compounds from verified sources like Real Peptides, it matters enough to verify those compounds aren't pushing your liver enzymes, glucose, or hormone levels into pathological ranges. The metabolic cost of skipping blood work isn't always immediate. But it's always measurable, and by the time subjective symptoms appear, the intervention window has often closed.